Researchers at Northwestern University have made advancements in the early intervention of Alzheimer’s disease through an experimental drug named NU-9. In a recently conducted study, scientists identified a novel subtype of toxic amyloid beta oligomers, which are clusters of proteins linked to the disease’s early progression, including neuronal dysfunction and inflammation.
NU-9, a small-molecule compound, was shown to significantly reduce the levels of this toxic oligomer subtype in a mouse model of Alzheimer’s disease. By targeting these changes before the onset of symptoms, researchers aim to prevent or delay the destructive processes that lead to neuronal loss.
The findings indicate a promising new approach to addressing Alzheimer's during its initial stages, as highlighted by Daniel Kranz, the study's first author. Current clinical trials often begin too late, according to Kranz, who emphasizes that the underlying pathology of Alzheimer's can be advanced by the time symptoms become apparent.
Additionally, the study revealed that NU-9 effectively reduced early markers of neuroinflammation and the presence of the abnormal protein TDP-43. The researchers suggest that by mitigating these early inflammatory responses, NU-9 could slow the progression of the disease.
The study will be published on December 18 in the journal Alzheimer's and Dementia. Further investigations are planned to explore NU-9's efficacy in different models of Alzheimer’s disease and its potential role as a preventive measure for individuals identified with early biomarkers of the condition.
This research builds on previous work where NU-9 showed promise in treating other neurodegenerative diseases, and it reflects a growing interest in early intervention strategies for Alzheimer’s, akin to preventive measures in cardiovascular health.